4SC AG Buchwert je Aktie
Was ist das Buchwert je Aktie von 4SC AG?
Buchwert je Aktie von 4SC AG ist 0.76
Was ist die Definition von Buchwert je Aktie?
Der Buchwert pro Aktie ist das Vermögen eines Unternehmens abzüglich der Verbindlichkeiten geteilt durch die Anzahl der ausstehenden Aktien.
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Buchwert je Aktie von Unternehmen in Health Care Sektor auf XETRA im Vergleich zu 4SC AG
Was macht 4SC AG?
4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company's products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. 4SC AG also out-licenses its products to pharma and biotech companies for the treatment of cancer. The company has a collaboration agreement with the Netherlands Cancer Institute to evaluate Domatinostat in the neoadjuvant setting in melanoma. 4SC AG was founded in 1997 and is headquartered in Planegg, Germany.
Unternehmen mit buchwert je aktie ähnlich 4SC AG
- Farmmi Inc hat Buchwert je Aktie von 0.75
- Hennes & Mauritz AB hat Buchwert je Aktie von 0.75
- Guyana Goldfields hat Buchwert je Aktie von 0.76
- SEM hat Buchwert je Aktie von 0.76
- Euroland Corporate Societe anonyme hat Buchwert je Aktie von 0.76
- Goldshore Resources hat Buchwert je Aktie von 0.76
- 4SC AG hat Buchwert je Aktie von 0.76
- NovoCure Ltd hat Buchwert je Aktie von 0.76
- Japara Healthcare hat Buchwert je Aktie von 0.76
- Acorn Capital Investment Fund hat Buchwert je Aktie von 0.76
- Taizhou Water Co Ltd hat Buchwert je Aktie von 0.76
- Lyra Therapeutics hat Buchwert je Aktie von 0.76
- Vulcan Steel Ltd hat Buchwert je Aktie von 0.76